Fady Ibraham Malik

EVP Research & Development

Fady Ibraham Malik (EVP Research & Development) filed 18 Form 4 reports in the trailing twelve months (0 purchases, 18 sales), most often in Cytokinetics, Incorporated (CYTK). The largest single filing was $748K of CYTK (12,033 sh across 2 lots, as filed), executed Mar 17.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 18 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$4.4M

shares × price, as filed

Last traded

Sep 8

Filed Sep 8

Median ADV $207.8M across their filed names

Open performance→

Volume by month

Buys $0 Sells $7.3M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 18 filings

Sector per market data · by filing · past 12 months

Most traded names

CYTK

Cytokinetics, Incorporated CYTK · 0 buys · 28 sells 28 filings

Recent filings

CYTKSALE Cytokinetics, Incorporated View filing → $310K
5,300 sh × $58.48
Exec Nov 12 2024
Filed Nov 13 2024 · 5:30 PM ET CYTKSALE Cytokinetics, Incorporated View filing → $379K
7,300 sh across 2 lots
Exec Oct 30 2024
Filed Oct 31 2024 · 5:30 PM ET CYTKSALE Cytokinetics, Incorporated View filing → $396K
7,300 sh across 2 lots
Exec Oct 15 2024
Filed Oct 16 2024 · 5:30 PM ET CYTKSALE Cytokinetics, Incorporated View filing → $380K
7,300 sh across 2 lots
Exec Oct 1 2024
Filed Oct 1 2024 · 5:30 PM ET